Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharma (CRNX)
NASDAQ:CRNX
CRNX Stock Chart & Stats
$48.18
-$0.61(-1.22%)
At close: 4:00 PM EST
$48.18
-$0.61(-1.22%)
Day’s Range― - ―
52-Week Range$24.10 - $57.99
Previous CloseN/A
Volume214.21K
Average Volume (3M)878.26K
Market Cap
$4.57B
Enterprise Value$3.86B
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$49.14M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 04, 2026EPS Estimate
-1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding94,891,840
10 Day Avg. Volume546,814
30 Day Avg. Volume878,261
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)3975.39
P/FCF Ratio-17.97
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue2.52K
Enterprise Value/Gross Profit2.52K
Enterprise Value/Ebitda-8.15
Forecast
1Y Price Target
$86.90Price Target Upside80.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Risk ReductionPhase 2 Cohort 4 and open-label extension data for atumelnant materially reduce risk for the Phase 3 program by showing robust biomarker reductions while patients remained on physiologic steroid doses.
Commercial Launch And Payer AccessInitial commercial launch of Palsonify showed stronger-than-expected early adoption with broad prescriber uptake and favorable payer approvals, supporting early revenue momentum.
Financial RunwayA reported multi-year cash reserve aimed to fund operations into 2029 reduces near-term financing pressure and supports continued development and commercialization activities.
Bears Say
Financing RiskHigh cash burn and uncertain revenue scalability create a potential need for additional capital, which could dilute shareholders or pressure the stock.
Investor Skepticism And VolatilityElevated short interest and disclosed potential conflicts in some analyses signal heightened market skepticism and could amplify share price volatility.
Safety ConcernA liver enzyme elevation in a higher-dose patient, despite resolving after treatment cessation, leaves a safety overhang that could increase regulatory and investor scrutiny.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharma’s price range in the past 12 months?
Crinetics Pharma lowest stock price was $24.10 and its highest was $57.99 in the past 12 months.
What is Crinetics Pharma’s market cap?
Crinetics Pharma’s market cap is $4.57B.
When is Crinetics Pharma’s upcoming earnings report date?
Crinetics Pharma’s upcoming earnings report date is Mar 04, 2026 which is in 56 days.
How were Crinetics Pharma’s earnings last quarter?
Crinetics Pharma released its earnings results on Nov 06, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$1.244 by -$0.136.
Is Crinetics Pharma overvalued?
According to Wall Street analysts Crinetics Pharma’s price is currently Undervalued.
Does Crinetics Pharma pay dividends?
Crinetics Pharma does not currently pay dividends.
What is Crinetics Pharma’s EPS estimate?
Crinetics Pharma’s EPS estimate is -1.33.
How many shares outstanding does Crinetics Pharma have?
Crinetics Pharma has 94,891,840 shares outstanding.
What happened to Crinetics Pharma’s price movement after its last earnings report?
Crinetics Pharma reported an EPS of -$1.38 in its last earnings report, missing expectations of -$1.244. Following the earnings report the stock price went down -8.025%.
Which hedge fund is a major shareholder of Crinetics Pharma?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.90 (80.37% Upside)
$86.90 (80.37% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.35%
12-Months-Change
Fundamentals
Return on Equity
-44.42%
Trailing 12-Months
Asset Growth
27.59%
Trailing 12-Months
Company Description
Crinetics Pharma
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CRNX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a successful launch and positive market reception of PALSONIFY, which is expected to drive substantial growth. However, delays in the Graves' disease candidate and the SST3 agonist program were noted. Overall, the sentiment is positive given the successful launch and financial stability.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$86.90
▲(80.37% Upside)
Technical Analysis
Ligand Pharma
―
Ultragenyx Pharmaceutical
―
Apellis Pharmaceuticals
―
―
Kymera Therapeutics
―
Ownership Overview
1.93% Insiders
39.72% Mutual Funds
37.10% Other Institutional Investors
6.12% Public Companies and Individual Investors